OpenLegislation

Regulation 145 Amendment of regulation 186 (reporting obligations on the licensing authority)I1F1

United Kingdom

In regulation 186—

(a)

in paragraph (1), for sub-paragraphs (d) and (e) substitute—

“(d)

submit reports of serious suspected adverse reactions in Northern Ireland that it has recorded under regulation 185 in relation to—

(i)

a UKMA(NI),

(ii)

a UKMA(UK),

(iii)

a THR(NI),

(iv)

a THR(UK), or

(v)

an Article 126a authorisation,

to the EMA before the end of the period of 15 days beginning on the day following the day on which the report was received; and

(e)

submit reports of non-serious suspected adverse reactions in Northern Ireland that it has recorded under regulation 185 in relation to—

(i)

a UKMA(NI),

(ii)

a UKMA(UK),

(iii)

a THR(NI),

(iv)

a THR(UK), or

(v)

an Article 126a authorisation,

to the EMA before the end of the period of 90 days beginning on the day following the day on which the report was received.”;

(b)

omit paragraph (4).

Annotations

Textual amendments

F1

Reg. 145 substituted (31.12.2020 immediately before IP completion day) by The Human Medicines (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1488), reg. 1, Sch. 2 para. 113

Commencement

I1

Reg. 145 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1